Physician profile
Emil Abdulhayoglu
NPI 1801860671
$7,870.37
in general payments reported to CMS, 2019-2025
15 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $1,152 · 2021: $159 · 2022: $1,640 · 2023: $2,296 · 2024: $1,760 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791 · Travel and Lodging: $1,346 · Education: $37.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.31 |
| Travel and Lodging | $1,345.75 |
| Education | $37.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,956.31 | 2021-2025 | Ellipsys Vascular Access System |
| Merit Medical Systems INC | $995.54 | 2020 | |
| Mozarc Medical US LLC | $874.72 | 2024 | Argyle |
| Horizon Therapeutics Plc | $410.97 | 2019-2021 | |
| Akebia Therapeutics INC | $158.18 | 2019 | |
| Mallinckrodt Enterprises LLC | $105.95 | 2019 | |
| Vifor Pharma, INC. | $80.34 | 2019 | |
| Medline Industries LP | $60.62 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $52.35 | 2019 | |
| Cormedix INC. | $48.02 | 2024 | Defencath |
| Opko Pharmaceuticals, LLC | $47.21 | 2019 | |
| Fresenius USA Marketing, INC. | $32.20 | 2019 | |
| Bard Peripheral Vascular, INC. | $16.20 | 2023 | Set Aspirex S 10f 110cm |
| Astrazeneca Pharmaceuticals LP | $15.93 | 2019 | |
| Amgen INC. | $15.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emil Abdulhayoglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.